Cayson Acquisition Corp (CAPN) Stock Price & Analysis
Cayson Acquisition Corp (CAPN) rose 0.00% to USD 11.1 as of July 25, 2026 at 15:41 UTC, according to Nexqual real-time market data.
CAPN last closed at USD 11.1; the session ranged USD 11.1–11.1 on volume of 44 shares. Market capitalization is $58.70M, with a 52-week range of USD 10.32–11.44 (NGM). Source: Nexqual, July 25, 2026 at 15:41 UTC.
Key Statistics (as of July 25, 2026 at 15:41 UTC)
| Price | USD 11.1 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 11.1 |
| Open | USD 11.1 |
| Day Range | USD 11.1 – 11.1 |
| 52-Week Range | USD 10.32 – 11.44 |
| Volume | 44 shares |
| Market Cap | $58.70M |
| Exchange | NGM |
Technical Analysis (CAPN)
Nexqual's technical model rates CAPN "BUY" based on 5 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 15:41 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Above (USD 11.01) |
| MACD | 0.02 (positive) |
Analyst Ratings (CAPN)
Wall Street analysts rate CAPN "None", per Nexqual as of July 25, 2026 at 15:41 UTC.
| Consensus Rating | None |
|---|
Earnings (CAPN)
Source: Nexqual, July 25, 2026 at 15:41 UTC.
Financials & Fundamentals (CAPN)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.09 |
| Total Cash | $64,433 |
| Total Debt | $1.32M |
Source: Nexqual, July 25, 2026 at 15:41 UTC.
Financial Health Score (CAPN)
Nexqual rates Cayson Acquisition Corp's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 15:41 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $64K cash vs $1M debt |
| Cash Flow | Weak — Operating cash flow -$251K |
| Efficiency | Mixed — No data |
Ownership (CAPN)
| Insider Ownership | +54.89% |
|---|---|
| Institutional Ownership | +63.77% |
| Shares Outstanding | 5.29M |
| Float | 2.45M |
| Short % of Float | +0.05% |
Source: Nexqual, July 25, 2026 at 15:41 UTC.
Leadership (CAPN)
Cayson Acquisition Corp is led by Yawei Cao (age 51), Chairman & CEO, per Nexqual as of July 25, 2026 at 15:41 UTC.
| Chairman & CEO | Yawei Cao (age 51) |
|---|---|
| Chief Financial Officer | Dahe Zhang (age 47) |
Major Backers & Investors (CAPN)
Notable institutional backers of Cayson Acquisition Corp include Berkley W R Corp, Mizuho Securities USA LLC, RiverNorth Capital Management, LLC, according to Nexqual as of July 25, 2026 at 15:41 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Berkley W R Corp | 9.4% |
| Mizuho Securities USA LLC | 9% |
| RiverNorth Capital Management, LLC | 8.51% |
| Wolverine Asset Management, LLC | 5.21% |
| Polar Asset Management Partners Inc. | 5.2% |
| Shaolin Capital Management LLC | 4.23% |
| AQR Arbitrage LLC | 3.49% |
| Heights Capital Management, Inc | 2.84% |
Source: Nexqual, July 25, 2026 at 15:41 UTC.
From Cayson Acquisition Corp's Latest SEC 10-K Filing (filed 2026-03-24)
Partnerships
- If any third party refuses to execute an agreement waiving such claims to the monies held in the Trust Account, our management will perform an analysis of the alternatives available to it and will only enter into an agreement with a third party that has not executed a waiver if management believes that such third party's engagement would be significantly more beneficial to us than any alternative.
- If our board of directors is not able to independently determine the fair market value of our initial Business Combination (including with the assistance of financial advisors), we will obtain an opinion from an independent investment banking firm or another independent entity that commonly renders valuation opinions with respect to the satisfaction of such criteria.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ANTH | ANTHERA PHARMACEUTICALS INC | USD 0 | ▲ 0% |
| GBIM | GLOBEIMMUNE INC | USD 0 | ▲ 0% |
| ICLD | INTERCLOUD SYSTEMS INC | USD 0 | ▲ 0% |
| BLFS | BioLife Solutions, Inc. | USD 29.98 | ▼ 3.76% |
| CANF | Can-Fite Biopharma Ltd | USD 3.19 | ▼ 3.33% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 15:41 UTC. This page is informational and not investment advice.